Bruising should be expected, as 84% of patients in clinical trials experienced bruising1
Injection Site Bruising
In clinical trials, 84% of subjects treated with QWO experienced injection site bruising. Subjects with coagulation disorders or using anticoagulant or antiplatelet medications (except those taking ≤150 mg aspirin daily) were excluded from participating in Trials 1 and 2.
QWO should be used with caution in patients with bleeding abnormalities or who are currently being treated with antiplatelet (except those taking ≤150 mg aspirin daily) or anticoagulant therapy.
In general, adverse events associated with QWO injection were mild to moderate and resolved within 2-3 weeks without treatment.1,3,11
No additional safety concerns were identified with six months of follow-up.1